Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

We conducted a phase 3 randomized controlled trial looking at the immunogenicity and safety of a novel combined Haemophilus influenzae type b and Neisseria meningitidis serogroup C tetanus toxoid conjugate vaccine, Hib-MenC-TT in a 2-, 3-, and 4-month primary infant immunization schedule. SBA MenC titers > or =1:8 and anti-PRP concentrations > or =0.15 microg/mL were measured in 99.2% and 100%, respectively, of the infants receiving Hib-MenC-TT.

Original publication




Journal article


Pediatr Infect Dis J

Publication Date





1057 - 1059


Antibodies, Bacterial, Diphtheria-Tetanus-Pertussis Vaccine, Haemophilus Infections, Haemophilus Vaccines, Haemophilus influenzae type b, Humans, Immunization, Immunization Schedule, Infant, Meningococcal Infections, Meningococcal Vaccines, Neisseria meningitidis, Serogroup C, Poliovirus Vaccine, Inactivated, Tetanus Toxoid, Vaccines, Combined, Vaccines, Conjugate